Glycemic control and BMI changes after endoscopic implantation of a duodenojejunal bypass liner compared with laparoscopic Roux-en-Y gastric bypass surgery: a propensity score matching analysis

Günthert, S; Aksan, A; Schröder, Oliver; Meyer, G.; Hausmann, Johannes; Stein, Jürgen M.; Stier, Christine

doi:10.1007/s00464-022-09177-y

Cited by 4 publications

(5 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In terms of metabolic effects, at 1 year of follow-up, glycemic control had improved significantly in both groups with no significant intergroup difference. 8 …”

Section: Comparison With Other Methodsmentioning

confidence: 99%

“…In terms of metabolic effects, at 1 year of followup, glyce mic control had improved significantly in both groups with no significant intergroup difference. 8 Current FDAapproved EBMTs include intragastric balloon, aspiration therapy, and gastric remodeling therapies such as en doscopic sleeve gastroplasty with the Apollo Overstitch sutur ing device (Apollo Endosurgery Inc.) as well as gastric suturing using the Endomina platform (Endo Tools Therapeutics S.A.). 13 The ASGE/American Society for Metabolic and Bariatric Sur gery (ASMBS) criteria for adopting EBMTs in clinical practice encompass a %EWL ≥25% versus the control group and an SAE rate ≤5%.…”

Section: Comparison With Other Methodsmentioning

confidence: 99%

“…A prior study reveal that DJBL use longer than 12 months (up to 24 months) increases the risk of adverse events without providing clinical benefits. 8 …”

Section: Device Characteristics and Endoscopic Placement/removalmentioning

confidence: 99%

“…The surgical approach also involves isolation of the cardia, a partial vagotomy, and exclusion of the distal stomach, while the DJBL delays gastric emptying. 8 , 17 …”

Section: Physiological Aspects/mechanism Of Actionmentioning

confidence: 99%

“…7 The endoscopic removal of the DJBL should be performed under general anesthesia and fluoroscopic assistance utilizing a devicespecific grasping tool within a suitable foreign body hood (similar to a large cap) positioned at the distal end of the gastroscope. 8 The device is ideally removed within 12 months unless early removal is required due to an adverse event. A pri or study reveal that DJBL use longer than 12 months (up to 24 months) increases the risk of adverse events without providing clinical benefits.…”

Section: A a B B C C D Dmentioning

confidence: 99%

See 4 more Smart Citations

Role of endoscopic duodenojejunal bypass liner in obesity management and glycemic control

Igi,

de Oliveira,

Matar

et al. 2024

Clin Endosc

View full text Add to dashboard Cite

The treatment of obesity and its comorbidities ranges from clinical management involving lifestyle changes and medications to bariatric and metabolic surgery. Various endoscopic bariatric and metabolic therapies recently emerged to address an important therapeutic gap by offering a less invasive alternative to surgery that is more effective than conservative therapies. This article comprehensively reviews the technical aspects, mechanism of action, outcomes, and future perspectives of one of the most promising endoscopic bariatric and metabolic therapies, named duodenojejunal bypass liner. The duodenojejunal bypass liner mimics the mechanism of Roux-en-Y gastric bypass by preventing food contact with the duodenum and proximal jejunum, thereby initiating a series of hormonal changes that lead to delayed gastric emptying and malabsorptive effects. These physiological changes result in significant weight loss and improved metabolic control, leading to better glycemic levels, preventing dyslipidemia and non-alcoholic fatty liver disease, and mitigating cardiovascular risk. However, concern exists regarding the safety profile of this device due to the reported high rates of severe adverse events, particularly liver abscesses. Ongoing technical changes aiming to reduce adverse events are being evaluated in clinical trials and may provide more reliable data to support its routine use in clinical practice.

show abstract

“…In terms of metabolic effects, at 1 year of follow-up, glycemic control had improved significantly in both groups with no significant intergroup difference. 8 …”

Section: Comparison With Other Methodsmentioning

confidence: 99%

Section: Comparison With Other Methodsmentioning

confidence: 99%

“…A prior study reveal that DJBL use longer than 12 months (up to 24 months) increases the risk of adverse events without providing clinical benefits. 8 …”

Section: Device Characteristics and Endoscopic Placement/removalmentioning

confidence: 99%

“…The surgical approach also involves isolation of the cardia, a partial vagotomy, and exclusion of the distal stomach, while the DJBL delays gastric emptying. 8 , 17 …”

Section: Physiological Aspects/mechanism Of Actionmentioning

confidence: 99%

Section: A a B B C C D Dmentioning

confidence: 99%

See 3 more Smart Citations